Larry Biegelsen
Stock Analyst at Wells Fargo
(3.86)
# 505
Out of 4,818 analysts
296
Total ratings
52.04%
Success rate
5.85%
Average return
Main Sectors:
Stocks Rated by Larry Biegelsen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RXST RxSight | Maintains: Equal-Weight | $22 → $17 | $14.48 | +17.40% | 12 | Apr 7, 2025 | |
| KMTS Kestra Medical Technologies | Initiates: Overweight | $28 | $24.34 | +15.04% | 1 | Mar 31, 2025 | |
| BLCO Bausch + Lomb | Downgrades: Equal-Weight | $24 → $15 | $12.78 | +17.42% | 5 | Mar 28, 2025 | |
| HYPR Hyperfine | Maintains: Equal-Weight | $1.1 → $1.29 | $0.77 | +67.53% | 4 | Mar 18, 2025 | |
| TNDM Tandem Diabetes Care | Downgrades: Equal-Weight | $38 → $22 | $16.57 | +32.77% | 8 | Mar 3, 2025 | |
| TFX Teleflex | Maintains: Equal-Weight | $214 → $146 | $133.00 | +9.77% | 4 | Feb 28, 2025 | |
| MMSI Merit Medical Systems | Maintains: Overweight | $120 → $117 | $93.79 | +24.75% | 8 | Feb 26, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $153 → $160 | $92.61 | +72.77% | 13 | Feb 21, 2025 | |
| PEN Penumbra | Maintains: Overweight | $275 → $305 | $278.77 | +9.41% | 17 | Feb 19, 2025 | |
| GEHC GE HealthCare Technologies | Maintains: Overweight | $96 → $103 | $64.89 | +58.73% | 3 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $198 → $195 | $148.57 | +31.25% | 11 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $118 | $98.87 | +19.35% | 13 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $10.93 | +55.54% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $427 → $435 | $357.11 | +21.81% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $630 → $687 | $487.93 | +40.80% | 19 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $166 → $152 | $155.24 | -2.09% | 13 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $10 → $8 | $4.98 | +60.64% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $94 | $67.25 | +39.78% | 9 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $118 | $80.94 | +45.79% | 16 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $106 → $98 | $83.72 | +17.06% | 17 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $110 → $117 | $99.54 | +17.54% | 9 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $80 | $70.46 | +13.54% | 15 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $94 → $105 | $93.73 | +12.02% | 8 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $44 → $40 | $29.65 | +34.91% | 15 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $40 | $17.70 | +126.05% | 17 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $49 | $16.32 | +200.34% | 2 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $136 | $129.82 | +4.76% | 21 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $70 | $71.90 | -2.64% | 7 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $279 → $270 | $202.51 | +33.33% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $101.35 | - | 2 | Nov 2, 2017 |
RxSight
Apr 7, 2025
Maintains: Equal-Weight
Price Target: $22 → $17
Current: $14.48
Upside: +17.40%
Kestra Medical Technologies
Mar 31, 2025
Initiates: Overweight
Price Target: $28
Current: $24.34
Upside: +15.04%
Bausch + Lomb
Mar 28, 2025
Downgrades: Equal-Weight
Price Target: $24 → $15
Current: $12.78
Upside: +17.42%
Hyperfine
Mar 18, 2025
Maintains: Equal-Weight
Price Target: $1.1 → $1.29
Current: $0.77
Upside: +67.53%
Tandem Diabetes Care
Mar 3, 2025
Downgrades: Equal-Weight
Price Target: $38 → $22
Current: $16.57
Upside: +32.77%
Teleflex
Feb 28, 2025
Maintains: Equal-Weight
Price Target: $214 → $146
Current: $133.00
Upside: +9.77%
Merit Medical Systems
Feb 26, 2025
Maintains: Overweight
Price Target: $120 → $117
Current: $93.79
Upside: +24.75%
Glaukos
Feb 21, 2025
Maintains: Overweight
Price Target: $153 → $160
Current: $92.61
Upside: +72.77%
Penumbra
Feb 19, 2025
Maintains: Overweight
Price Target: $275 → $305
Current: $278.77
Upside: +9.41%
GE HealthCare Technologies
Feb 14, 2025
Maintains: Overweight
Price Target: $96 → $103
Current: $64.89
Upside: +58.73%
Feb 11, 2025
Maintains: Equal-Weight
Price Target: $198 → $195
Current: $148.57
Upside: +31.25%
Feb 6, 2025
Maintains: Overweight
Price Target: $100 → $118
Current: $98.87
Upside: +19.35%
Jan 30, 2025
Maintains: Overweight
Price Target: $13 → $17
Current: $10.93
Upside: +55.54%
Jan 29, 2025
Maintains: Overweight
Price Target: $427 → $435
Current: $357.11
Upside: +21.81%
Jan 24, 2025
Maintains: Overweight
Price Target: $630 → $687
Current: $487.93
Upside: +40.80%
Jan 23, 2025
Maintains: Equal-Weight
Price Target: $166 → $152
Current: $155.24
Upside: -2.09%
Dec 11, 2024
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $4.98
Upside: +60.64%
Dec 11, 2024
Maintains: Overweight
Price Target: $90 → $94
Current: $67.25
Upside: +39.78%
Dec 6, 2024
Maintains: Overweight
Price Target: $115 → $118
Current: $80.94
Upside: +45.79%
Nov 20, 2024
Maintains: Overweight
Price Target: $106 → $98
Current: $83.72
Upside: +17.06%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $110 → $117
Current: $99.54
Upside: +17.54%
Sep 9, 2024
Maintains: Overweight
Price Target: $90 → $80
Current: $70.46
Upside: +13.54%
Aug 22, 2024
Maintains: Overweight
Price Target: $94 → $105
Current: $93.73
Upside: +12.02%
Aug 7, 2024
Maintains: Equal-Weight
Price Target: $44 → $40
Current: $29.65
Upside: +34.91%
Jul 26, 2024
Maintains: Overweight
Price Target: $42 → $40
Current: $17.70
Upside: +126.05%
Dec 5, 2023
Upgrades: Overweight
Price Target: $40 → $49
Current: $16.32
Upside: +200.34%
Apr 5, 2023
Maintains: Overweight
Price Target: $140 → $136
Current: $129.82
Upside: +4.76%
May 11, 2022
Maintains: Overweight
Price Target: $80 → $70
Current: $71.90
Upside: -2.64%
Apr 8, 2020
Maintains: Overweight
Price Target: $279 → $270
Current: $202.51
Upside: +33.33%
Nov 2, 2017
Upgrades: Outperform
Price Target: n/a
Current: $101.35
Upside: -